PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
27154061-0	2016	ADRB2 signaling promotes HCC progression and sorafenib resistance by inhibiting autophagic degradation of HIF1alpha.	Sorafenib	45-54	adrenergic receptor, beta 2	Mus musculus	0-5	
27154061-10	2016	Notably, ADRB2 signaling negatively regulated autophagy by disrupting Beclin1/VPS34/Atg14 complex in an Akt-dependent manner, leading to HIF1alpha stabilization, reprogramming of HCC cells glucose metabolism, and the acquisition of resistance to sorafenib.	Sorafenib	246-255	adrenergic receptor, beta 2	Mus musculus	9-14	
27154061-11	2016	Conversely, inhibition of ADRB2 signaling by ICI118,551, or knockdown ADRB2 expression, led to enhanced autophagy, HIF1alpha destabilization, tumor growth suppression, and improved anti-tumor activity of sorafenib.	Sorafenib	204-213	adrenergic receptor, beta 2	Mus musculus	26-31	
27154061-11	2016	Conversely, inhibition of ADRB2 signaling by ICI118,551, or knockdown ADRB2 expression, led to enhanced autophagy, HIF1alpha destabilization, tumor growth suppression, and improved anti-tumor activity of sorafenib.	Sorafenib	204-213	adrenergic receptor, beta 2	Mus musculus	70-75	
27154061-14	2016	Given the efficacy of ADRB2 modulation on HCC inhibition and sorafenib resistance, adrenoceptor antagonist appears to be a putative novel treatment for HCC and chemoresistance.	Sorafenib	61-70	adrenergic receptor, beta 2	Mus musculus	22-27	
27154061-16	2016	ADRB2 signaling negatively regulated autophagy, leading to hypoxia-inducible factor-1alpha stabilization, reprogramming of hepatocellular carcinoma cells glucose metabolism, and the acquisition of resistance to sorafenib.	Sorafenib	211-220	adrenergic receptor, beta 2	Mus musculus	0-5